SINGAPORE – December 9, 2014 – For the sixth time in eight years, Quintiles has been named Asia-Pacific Contract Research Organization of the Year by Frost & Sullivan, a leading business research and consulting firm. The award honors the CRO that scores the highest in Frost & Sullivan’s evaluation of several performance categories, including customer service; price/performance value; pioneering best practices; and addressing unmet needs.Frost & Sullivan 2014 Best Practices Awards

Frost & Sullivan cited Quintiles’ local market knowledge; its Asia-Pacific capabilities that complement its global offering; and its ability to provide solutions to meet customers’ most pressing needs as some of the reasons why Quintiles was selected as 2014 CRO of the Year.

“I’d like to thank our 10,000 employees across Asia-Pacific for their efforts – we owe this honor to them,” said Anand Tharmaratnam, M.D., head of Quintiles Asia-Pacific. “We have grown our market leadership position in the region by investing early, developing a local talent base that is leveraged globally, and partnering with our customers to expand in Asia-Pacific. It’s wonderful to see the efforts of our employees and our leadership team validated by this award.”

Rhenu Bhuller, senior vice president of Healthcare at Frost & Sullivan, said: “Advances in technology are transforming the global healthcare industry. We are seeing a growing focus on healthcare innovation in Asia-Pacific, with Quintiles being one of the leaders. Quintiles is using technology to link its globally integrated service offerings with local market expertise to meet local customer needs.

“This allows Quintiles to work not only with large multinational biopharma companies in Asia-Pacific but also with emerging local companies with regional or global aspirations, which we see as the growth engine for the life sciences industry.”

In 2014 Quintiles has been named the Best CRO in Asia at the BioPharma Industry Awards (winning for the third time in four years); honored as a top employer in South Korea by the Great Place to Work Institute; and received the SCRIP Awards Best CRO honors (winning for fourth time in five years), among other awards. Quintiles opened its first Asia-Pacific office (Tokyo) in 1993 and now operates in 13 countries across Asia-Pacific.

About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit

Jay Johnson, Media Relations (

Karl Deonanan, Investor Relations (